Table 2.
Correlation of PGE2 and Phase I, Phase II, COX-1, and COX-2 levels in SILASTIC and injected animals
| Treatment | Phase I | Phase II | COX-1 | COX-2 |
|---|---|---|---|---|
| Chronic | ||||
| Overall | R2=.079; m=−1.216 ± 1.309 | R2=.857−3; m=−.845 ± 9.131 | R2=.323; m=−.001 ± .706−3 | R2=.064; m=.001 ± .001 |
| Vehicle | R2=.525; m=−5.147 ± 2.444 | R2=.161; m=−17.11 ± 19.51 | R2=.731; m=−.003 ± .693−3 | R2=.538; m=−.002 ± .826−3 |
| Estradiol | R2=.031; m=.404 ± 1.130 | R2=.222; m=5.224 ± 4.885 | R2=.007; m=−.243−3 ± .001 | R2=.703; m=.005 ± .001 |
| Acute | ||||
| Overall | R2=.224; m=.068 ± .040 | R2=.147; m=.300 ± .227 | R2=.099; m=.197−3 ± .148−3 | R2=.033; m=.511−4 ± .687−4 |
| Vehicle | R2=.045; m=.168 ± .387 | R2=.009; m=.413 ± 2.109 | R2=.424; m=.002 ± .753−3 | R2=.172; m=.573−3 ± .397−3 |
| Estradiol | R2=.600; m=.106 ± .043 | R2=.621; m=.566 ± .220 | R2=.234; m=.198−3 ± .135−3 | R2=.162; m=.716−4 ± .615−4 |
Bold items indicate significant correlations (P<.05). m=slope.